Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Wolfspeed Inc (WOLF) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Wolfspeed Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Wolfspeed Inc trades at $34 (market cap $1.83B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 21.8× Wolfspeed Inc's market cap, and Wolfspeed Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | WOLF | |
|---|---|---|
Market Cap | $39.89B | $1.83B |
Sector | Health | Technology |
52-Week High | $491.22 | $73.68 |
52-Week Low | $278.09 | $1.19 |
Enterprise Value | $38.15B | $2.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
WOLF stock trades at $35.29, down 5.26% amid a bearish technical signal. The company faces financial challenges with negative gross and net income margins but shows strategic shifts toward AI data centers and defense markets. Recent news highlights a patent lawsuit against Navitas and a collaboration with GE Aerospace, indicating active business development. Technical indicators show mixed signals with key support at $34.
The outlook is cautious due to persistent losses and competitive pressures, though analyst sentiment is mixed with a slight buy bias. Key risks include cash burn and market volatility, while opportunities lie in strategic pivots to high-growth sectors. Investors should weigh the potential from new initiatives against fundamental weaknesses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Wolfspeed Inc
Wolfspeed is the global leader in wide bandgap semiconductors, specializing in silicon carbide (SiC) and gallium nitride (GaN) materials and devices. It operates a vertically integrated model, controlling the entire process from raw material substrate production to advanced power modules, serving as a critical infrastructure provider for electric vehicles (EVs), renewable energy, and AI data centers.
Read more on WOLF →
